Literature DB >> 18334518

Age-related macular degeneration: diagnosis and management.

H L Cook1, P J Patel, A Tufail.   

Abstract

BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of blind registration in Western Europe and the third leading cause of blindness worldwide.
METHODS: The management of AMD is discussed with a review of current and new treatments.
RESULTS: Although there is no treatment for advanced dry AMD (geographic atrophy), there have been considerable advances in the management of neovascular AMD (nAMD). Established therapies for nAMD include laser photocoagulation and photodynamic therapy (PDT), but these have largely been superseded by agents which block the action of vascular endothelial growth factor (anti-VEGF agents). Current preventative strategies involve cessation of smoking and use of specific nutritional supplements to reduce the risk of developing nAMD.
CONCLUSIONS: There have been exciting advances in the treatment of nAMD and increased understanding of the genetics and pathogenic mechanisms involved will hopefully lead to the development of new therapies in the future.

Entities:  

Mesh:

Year:  2008        PMID: 18334518     DOI: 10.1093/bmb/ldn012

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  44 in total

Review 1.  Progressing a human embryonic stem-cell-based regenerative medicine therapy towards the clinic.

Authors:  Paul Whiting; Julie Kerby; Peter Coffey; Lyndon da Cruz; Ruth McKernan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

2.  Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration.

Authors:  Rosalia Giustolisi; Nicoletta Fantozzi; Mariateresa Staltari; Jessica Marchiori; Olga Mastrangelo; Roberta Marcucci; Federica Mirra; Paola Mazzotta; Corrado Balacco Gabrieli
Journal:  Digit J Ophthalmol       Date:  2011-09-30

3.  Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.

Authors:  Akiko Miki; Shigeru Honda; Hiroshi Kojima; Masaya Nishizaki; Tomoko Nagai; Masashi Fujihara; Mamoru Uenishi; Mihori Kita; Yasuo Kurimoto; Akira Negi
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

4.  [Long-term results in neovascular age-related macular degeneration : Changes in visual acuity and geographic atrophy during long-standing anti-VEGF therapy].

Authors:  V Thalgott; N Feucht; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

5.  One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Wataru Matsumiya; Shigeru Honda; Keiko Otsuka; Akiko Miki; Takayuki Nagai; Hisanori Imai; Sentaro Kusuhara; Makoto Nakamura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-30       Impact factor: 3.117

6.  Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Shunichiro Nakai; Wataru Matsumiya; Akiko Miki; Shigeru Honda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2019-08-02       Impact factor: 2.447

Review 7.  Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

8.  The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration.

Authors:  Kyung Hwa Kang; Greg Lemke; Jin Woo Kim
Journal:  Trends Mol Med       Date:  2009-04-18       Impact factor: 11.951

Review 9.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

10.  Endogenous leukemia inhibitory factor protects photoreceptor cells against light-induced degeneration.

Authors:  Sandra Bürgi; Marijana Samardzija; Christian Grimm
Journal:  Mol Vis       Date:  2009-08-18       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.